Ropinirole

Generic Name: Ropinirole

Brand Names: Requip

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₄N_₂O

CAS Number: 91374-21-9

Unique Ingredient Identifier: 030PYR8953

Background: Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome .

In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .

Indication: For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .

Associated Conditions: Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)

Clinical Trials

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Phase 3

Completed

Conditions: Restless Legs Syndrome (RLS)
Restless Legs Syndrome

Interventions: Drug: Ropinirole IR 2 mg
Drug: Ropinirole IR 1 mg
Drug: Ropinirole IR 2 mg Placebo
Drug: Ropinirole IR 1 mg Placebo
Drug: Ropinirole CR 2 mg
Drug: Ropinirole CR 3 mg
Drug: Ropinirole CR 3 mg Placebo
Drug: Ropinirole CR 2 mg Placebo

First Posted Date: 2005-11-22

Last Posted Date: 2019-03-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 135

Registration Number: NCT00256854

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-26

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 140

Registration Number: NCT00225862

Locations: 🇺🇸
GSK Investigational Site, Wenatchee, Washington, United States

Trial of Ropinirole in Motor Recovery After Stroke

Phase 2

Completed

Conditions: Cerebrovascular Accident
Hemiparesis

First Posted Date: 2005-09-22

Last Posted Date: 2016-11-01

Lead Sponsor: University of California, Irvine

Target Recruit Count: 52

Registration Number: NCT00221390

Locations: 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-20

Last Posted Date: 2016-09-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 380

Registration Number: NCT00197080

Locations: 🇨🇦
GSK Investigational Site, Regina, Saskatchewan, Canada

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Mirapex
Drug: Requip

First Posted Date: 2005-09-05

Last Posted Date: 2014-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 246

Registration Number: NCT00144300

Locations: 🇺🇸
248.538.00010 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸
248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸
248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 18 locations